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The gold standard for diagnosing cystic fibrosis (CF) is a sweat chloride value above 60mEq/L. However, this historical and
important tool has limitations; other techniques should be studied, including the nasal potential difference (NPD) test. CFTR gene
sequencing can identify CFTRmutations, but this method is time-consuming and too expensive to be used in all CF centers. The
present study compared CF patients with two classes I-III CFTRmutations (10 patients) (G1), CF patients with classes IV-VI CFTR
mutations (five patients) (G2), and 21 healthy subjects (G3). The CF patients and healthy subjects also underwent the NPD test. A
statistical analysis was performed using the Mann-Whitney, Kruskal-Wallis, 𝜒2, and Fisher’s exact tests, 𝛼 = 0.05. No differences
were observed between the CF patients and healthy controls for the PDMax, Δamiloride, and Δchloride + free + amiloride markers
from the NPD test. For the finger value, a difference between G2 andG3 was described.TheWilschanski index values were different
between G1 and G3. In conclusion, our data showed that NPD is useful for CF diagnosis when classes I-III CFTR mutations are
screened. However, if classes IV-VI are considered, the NPD test showed an overlap in values with healthy subjects.
1. Introduction
Cystic fibrosis (CF) (MIM: number 219700) is an autosomal
disorder with high clinical variability that is associated with
CFTR mutations, environmental effects, and modifier genes
[1–12]. Since 1989 [13–15], the discovery of the CFTR (cystic
fibrosis transmembrane regulator; 7q31.2 region) gene and
medical advances in CF knowledge have shown that CF is a
disease with complex clinical presentation [1–3]. Since 1959,
CF diagnosis has been obtained using the Gibson and Cooke
test, that is, the sweat test [16]. The sweat test is an important
tool that provides a CF diagnosis in the majority of patients
at a low cost. However, in cases of nonclassic CF disease,
specifically cases caused by class IV, V, or VI CFTRmutations
[17–19], patients can show normal chloride values in their
sweat [20].
Complete CFTR gene sequencing can provide a CF diag-
nosis. However, it is expensive, is time-consuming, and may
not be possible in all CF centers around the world.Therefore,
other tools are being studied for CF diagnosis, including the
following: (i) the concentrations of chloride and sodium in
the saliva [21]; (ii) 𝛽-adrenergic sweat secretion [22]; (iii)
measurements of CFTR-mediated chlorite (Cl) secretion in
human rectal biopsies [20]; (iv) newborn screening (NBS)
by assessing immunoreactive trypsinogen (IRT) (that is,
following a positive IRT, the sweat test should be performed
for CF diagnosis confirmation [23]); and (v) sequencing of
the entire CFTR gene [24]. In developing countries, a CF
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diagnosis can be obtained by measuring chloride and
sodium levels and usually by performing an F508del (cDNA:
c.1521 1523delCTT) mutation screening [25, 26].
The nasal potential difference (NPD) measurement is a
diagnostic method that is sensitive and specific, validates
CFTR function, and provides in vivo evidence of abnormal
ion transport due to the dysfunction of the CFTR protein
in nasal epithelial cells. For clinical management, a com-
parison among several CFTR biomarkers shows that NPD
reflects the CFTR function in the respiratory tract, an organ
strongly related to CF survival. However, NPD has not been
extensively assessed for its reproducibility and reliability for
diagnosis.There is an absence of validation for diagnosis, and
in the literature there is some correlation with respiratory
clinical endpoints. However, this tool is by far the most
extensively validated biomarker [27] and was used success-
fully to measure CFTR modulator therapy with ivacaftor in
patients withG551DCFTRmutations [28, 29]. NPD is used to
measure the voltage across the nasal epitheliumwhich results
from transepithelial ion transport and partially reflects CFTR
function [30]. Electrophysiological abnormalities in CF were
described nearly 50 years ago and correlate with features of
the CF phenotype.
Considering CF diagnoses in an admixed population, our
study compared three groups of subjects (patients with two
class I, II, or III CFTR mutations (group A); patients with at
least one class IV, V, or VI CFTRmutation (group B); healthy
subjects (group C)) in association with NPD. The aim of the
study was to verify the effectiveness of NPD to differentiate
healthy individuals from those with severe CFmutations and
with mild CF mutations.
2. Materials and Methods
2.1. Cystic Fibrosis Patients and Control Subjects. The CF
patient group initially included 21 patients based on CF
clinical characteristics and sodium and chloride values above
60mEq/L on the sweat test. F508del screening and CFTR
sequencing were performed in 15 of the 21 CF patients;
six (28.57%) patients were excluded. The CF population
ultimately included 15 CF patients (group A: 10 patients and
group B: five patients).TheCFTR genotypewas used to assign
patients to the groups and to enable a comparison between
classic and nonclassic CF.We also enrolled 21 healthy subjects
without CF or other diseases and with no familial history of
CF (group C).
Individual factors such as smoking, previous sinus sur-
gery, nasal polyposis, or acute upper respiratory tract infec-
tion have a negative influence on CFTR response [27]. In
this context, all patients and healthy controls with these
conditions were excluded from our analyses. The project
was approved by the University Ethics Committee (number
279/2007), and all of the patients and/or their guardians
signed an informed consent before inclusion in the study.
2.2. Molecular Analysis. A peripheral blood sample was
collected from each subject. Genomic DNA was obtained
by direct extraction from peripheral blood lymphocytes
according to standard procedures [31]. CFTRmutations were
determined in the following order: F508del identification
using the primers forward 5󸀠-GGC ACC ATT AAA GAA
AAT ATC-3󸀠 and reverse 5󸀠-TGG CAT GCT TTG ATG ACG
C-3󸀠 [25, 26]; CFTR exon sequencing, including exon/intron
boundaries, performed as previously described [24, 32, 33];
duplication, deletion, and LOH identification using the
SALSA MLPA Kit P091-C1 CFTR-MRC-Holland (MRC-
Holland, Willem Schoutenstraat, DL Amsterdam, Nether-
lands) performed according to the manufacturer instruc-
tions; and 1584–18672 pb A>G (intron 10) identification
performed as previously described [34].
2.3. Nasal Potential Difference Measurements. For the NPD
measurement, we used a high-impedance voltmeter with
a storage capacity for 100 data points (Knick Portamess
913, E) and AgCl electrodes with low impedance (less than
103 ohms). The voltmeter was set to record readings every
10 sec, and the measurements were transferred to a com-
puter and stored using Paraly SW105 software (ProMinent
Dosiertechnik GmbH, Germany).
Electrode 1 (reference) was positioned and fixed on the
anterior left forearm in scarified skin by a diamond-tip
drill for odontology use. Electrode 2 (exploring electrode)
was positioned within of the larger channel of a silicone
probe filled with a cream conductor (Sigma Electrode Cream,
Parker Laboratories).
We conducted finger measurements with electrode 2
between the thumb and index finger, which were soaked
in the conductor cream, and we then positioned the probe
tip 3.0 cm, 2.0 cm, 1.5 cm, 1.0 cm, and 0.5 cm below and
posterior to the right inferior turbinate with the aid of a
rigid nasal endoscope. NPD measurements in all positions
were achievedwhen themeasurement had stabilized formore
than five sec. The maximum potential difference (PDMax)
was considered the most negative measure. The probe was
released at a position of 1.5 cm.
The reference electrode was an isotonic NaCl- or Ringer’s
saline-perfused bridge in the subcutaneous space of the lower
arm. The reference bridge was 19 to 24 ga. needle contain-
ing isotonic Ringer’s saline. The exploring electrode was
an isotonic NaCl-/Ringer’s saline-perfused exploring bridge
positioned on the airway surface. Exploring bridges were
prepared either by filling lengths of polyethylene (PE) tubing
(PE-50 to PE-160) with 3M KCl in 4% agar or by a fluid-
filled double-lumen catheter continuously perfused with
warmed (24–37∘C) gassed isotonic NaCl/Ringer’s saline (0.2–
0.4mL/min). Contact with the nasal surface was ensured
by perfusion. The exploring bridge consisted of a vinyl
catheter (e.g., an umbilical vessel catheter, 5Ch 1.7mm).Most
catheters can be used repeatedly following gas sterilization
[35].
For the probe, five solutions were infused inside the nasal
cavity with a flow rate of five mL/min, which was controlled
by an infusion pump previously heated to a final temperature
of 37∘C. Each solution was sequentially infused for three
min with no pauses between the infusions. Solution A was
custom Ringer’s: 135mM NaCl; 1.2mM MgCl
2
; 2.25mM
CaCl
2
; 2.4mM K
2
HPO
4
; and 0.4mM KH
2
PO
4
. Solution
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B was 0.1mM amiloride hydrochloride (HCl) in Ringer’s
solution. Solution C was zero Cl− solution (+ amiloride):
135mM sodium gluconate, 1.2mM MgSO
4
, 2.2mM calcium
gluconate, 2.4mM K
2
HPO
4
, 0.4mM KH
2
PO
4
, and 0.1mM
amiloride HCl. Solution D was 0.01mM isoproterenol HCl
in solution C (caution: vials of isoproterenol contain Cl−).
Solution E was 0.1mM ATP in solution D.The mean pH was
7.4, with a range of 7.0–7.6. Solutions A, B, and C may have
been refrigerated for up to three months or frozen for up to
six months, whereas solutions D and E were freshly prepared
within two h prior to use. Prior to use, all the solutions were
filtered with 0.22𝜇m filter [35].
The voltmeter was programmed to obtain an NPD
measurement every 10 seconds, for a total of 18 measure-
ments for each solution. These values were immediately
transferred after each examination to a desktop computer
and stored. The NPD test was performed in the right nasal
cavity for all the subjects included in the study. The same
professional was responsible for performing all the tests. The
NPD tests analyzed the following variables: finger, PDMax,
Δchloride + free + amiloride, and Wilschanski index. In this
context, NPD changes were recorded after perfusion with
the following solutions: 100 𝜇M amiloride in saline solution
(Δamiloride), a chloride-free solution with 100𝜇Mamiloride
(Δchloride-free), and 100 𝜇M amiloride plus 10 𝜇M isopro-
terenol in a chloride-free solution (Δisoproterenol). The sum
of the Δchloride-free and Δisoproterenol values (Δchloride-
free-isoproterenol) served as an index of transepithelial
CFTR-dependent chloride transport because it reflected the
cAMP activation of nasal mucosa chloride permeability. The
Wilschanski index was calculated by the following formula:
eΔchloride/Δamiloride [36].
The published SOP-NPD (standard operation patroniza-
tion) [37] was not considered in the present study because
this technique was not viable in our center. All test conditions
followed previously published NPD requirements [35].
2.4. Clinical Markers. We clinically evaluated the CF patients
according to the following clinical severity markers: clinical
scores (Shwachman-Kulczycki, Kanga, and Bhalla) [38]; body
mass index (BMI) (for patients older than 19 years, the
BMI = weight/(height)2 formula was used; for the remaining
patients, the WHO AnthroPlus was used (children from 7 to
19 years old)); patient age and age at diagnosis (according
to sodium and chloride alterations in perspiration; first
clinical symptoms (digestive and pulmonary disease); the
period up to the 1st colonization by Pseudomonas aeruginosa;
the presence of microorganisms in the sputum (mucoid
and nonmucoid P. aeruginosa, Achromobacter xylosoxidans,
Burkholderia cepacia, and Staphylococcus aureus)); transcu-
taneous oxygen saturation; pulmonary function tests; CF
comorbidities (nasal polyps, osteoporosis, meconium ileus,
diabetes mellitus, and pancreatic insufficiency); race; and
gender.
The spirometry proof was performed using a model
CPFS/D speedometer (Med Graphics, Saint Paul, Minnesota,
USA).Thedatawere recorded usingBREEZEPF version 3.8 B
software for Windows 95/98/NT with the inclusion of the
followingmarkers: forced vital capacity (FVC) (%), the forced
expiratory volume in the first second (FEV
1
) (%), the ratio of
FEV
1
to FVC, and the forced expiratory flow between 25 and
75% of the FVC (FEF
25–75%).
2.5. Statistical Analysis. The statistical analysis was per-
formed with statistical package for the social sciences (SPSS)
software v.21.0 (version 21, SPSS Inc., Chicago, IL). The
sample power was determined using GPower 3.0.1 software
[39]. Based on the results of the Kruskal-Wallis test as a
parameter for population power estimation, for a sample size
of 36 subjects, with the 𝛼 error equal to 0.05, and an effect
size of 0.5, the statistical power of all the tests performed was
0.812.
The data were compared using the Mann-Whitney (com-
parison between GA versus GB, GA versus GC, and GB
versus GC) and Kruskal-Wallis tests (comparison amongGA,
GB, and GC) for the NPD variables. To avoid spurious data
due to themultiple tests performed [40], the significance level
𝛼 was adjusted by the Bonferroni correction (𝛼 corrected =
0.05/number of tests).
The clinical markers are shown as percentages for the
categorical data and as themeans, standard deviations, medi-
ans, and minimum and maximum values for the numerical
data. The statistical association between the GA and GB
was determined using the 𝜒2 test and Fisher’s exact test for
the categorical data and the Mann-Whitney 𝑈 test for the
numerical data.
3. Results
3.1. Patient Characterization andCFTRMutations. Our study
included 15 patients (seven (46.67%) males) with CF and 21
healthy controls (seven (33.33%)males).The complete patient
characteristics and the comparison between GA and GB are
presented in Tables 1 and 2, respectively.
The CF patients were divided into two groups according
to mutations identified in the CFTR gene. The patients with
two class I, II, or III CFTR mutations were designated for
group A (10 CF patients) and those with at least one class IV,
V, or VI CFTRmutation were designated for group B (five CF
patients). The healthy subjects were classified as group C.
In the GA, the following CFTR genotypes were
observed: F508del/F508del (eight (80%) patients (class
II)), F508del/1717-1G>A (one (10%) patient (mutation class
II/class I)), and F508del/G542X (one (10%) patient (mutation
class II/class I)) (Figure 1(a)).
In the GB, the following CFTR genotypes were observed:
F508del/1812-1G>A (one patient (class II mutation/uncertain
class)), F508del/3272-26A>G (one patient (mutation class
II/class V)), F508del/D1152H (one patient (mutation class
II/IV)), F508del/P205S (one patient (mutation class II/IV)),
and V562I/IVS8-5T (one patient (uncertain/class V)). Each
genotype corresponded to 20% of patients with class IV, V, or
VI CFTRmutations (Figure 1(a)).
The mutation characteristics are shown in Table 3.
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Figure 1: (a) CFTRmutations distributed by exon/intron localization and class. (b) CFTR gene with exon and intron descriptions. (c) CFTR
protein domains. (d) For all the data, consider the following: (A) cystic fibrosis patients with two class I, II, or III CFTRmutations; (B) cystic
fibrosis patients with two class IV, V, or VI CFTRmutations; and (C) healthy subjects.The comparison was made using the Mann-Whitney𝑈
test considering the following associations: A versus B, A versus C, and B versus C. 𝛼 considered was 0.05. For the finger (mV), ∗𝑃 = 1; #𝑃 =
0.021; ¥𝑃 = 0.003. For the PDMax (mV), 𝑃 = 0.426; #𝑃 = 0.040; ¥𝑃 = 0.416. For the Δamiloride (mV), ∗𝑃 = 0.394; #𝑃 = 0.554; ¥𝑃 = 0.474. For
the Δchloride-free + isoproterenol, ∗𝑃 = 0.390; #𝑃 = 0.007; ¥𝑃 = 0.125. For the Wilschanski index, ∗𝑃 = 0.050; #𝑃 = 0.002; ¥𝑃 = 0.345. The
maximum difference was observed by finger (B versus C) and for theWilschanski index (A versus C). CFTR = cystic fibrosis transmembrane
regulator, MSD = membrane-spanning domains, NBD = nucleotide-binding domains, R = regulator, and mV = millivolts.
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Table 1: Clinical and laboratory characteristics of the cystic fibrosis patients enrolled in the study∗.
Gender (male) 15 7 (46.7%)
Race (Caucasian) 15 15 (100%)
Age (months) 15 213.13 ± 122.03; 171 (87–443)
Onset of symptoms (months) 14 6.93 ± 13.28; 1 (0–39)
Onset of pulmonary symptoms (months) 14 10.86 ± 19.21; 3 (0–69)
Onset of digestive symptoms (months) 12 19.92 ± 38.57; 1 (0–120)
Diagnosis (months) 14 54.14 ± 101.95; 8,50 (1–378)
Body mass index (normal values) 15 12 (80%)
Nasal polyposis (presence) 15 3 (20%)
Diabetes mellitus (presence) 15 2 (13.3%)
Osteoporosis (presence) 15 3 (20%)
Pancreatic insufficiency (presence) 15 13 (86.7%)
Meconium ileus (presence) 15 3 (20%)
Pseudomonas aeruginosa 15 10 (66.7%)
Mucoid P. aeruginosa 15 8 (53.3%)
Achromobacter xylosoxidans 15 2 (13.3%)
Burkholderia cepacia 15 4 (26.7%)
Staphylococcus aureus 15 12 (80%)
Weight (kg) 15 43.67 ± 17.02; 34 (21–70)
Height (m) 15 1.58 ± 0.50; 1 (1-2)
Body mass index 15 18.35 ± 2.67; 17.75 (14.33–21.60)
SpO2 14 96.07 ± 1.64; 96 (94–98)
Bhalla 11 8.82 ± 4.75; 10 (0–17)
Kanga 13 22.54 ± 12.16; 21 (12–60)
Shwachman-Kulczycki 13 69.23 ± 12.39; 65 (50–90)
FVC 15 84.60 ± 22.02; 82 (57–131)
FEV1 15 76.40 ± 25.84; 72 (30–132)
FEV1/FVC 14 78.36 ± 19.17; 85 (37–100)
FEF
25–75% 14 59.50 ± 34.25; 57,50 (70–118)
∗The data are shown as𝑁 (percentage) for the categorical data and as the mean ± standard deviation and the median (minimum and maximum) values for
the numerical data. 𝑁: number of patients; SpO2: blood oxygen saturation; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second;
FEF25–75%: forced expiratory flow between 25 and 75% of the FVC.
3.2. Nasal Potential Difference. The data collected using the
NPD test are shown in Table 4 and Figure 1.
Table 4 shows the values of mean, standard deviation,
maximum, and minimum as well as confidence intervals of
probability from the comparison of the CF patient groups
and the healthy subjects for the following NPD variables:
finger (𝑃 = 0.020), PDMax (𝑃 = 0.111), Δamiloride (𝑃 = 1),
Δchloride-free-isoproterenol (𝑃 = 0.08), and Wilschanski
index (𝑃 = 0.025).
The complete data are shown in Figure 1(d). For the finger
values, there were significant differences between GA versus
GB (𝑃 = 0.021) and GB versus GC (𝑃 = 0.003). For the
PDMax, there was a significant difference in GA versus GB
(𝑃 = 0.04). For Δamiloride, no difference was observed.
For Δchloride-free-isoproterenol, there was a significant
difference in GA versus GB (𝑃 = 0.007). For the Wilschanski
index, there were significant differences between GA versus
GC (𝑃 = 0.050) and GA versus GB (𝑃 = 0.002).
4. Discussion
Identifying, standardizing, and unifying diagnostic tools for
chronic diseases, especially FC, are a constant and ongoing
effort in biological research. Even today, diagnosing CF in
some individuals remains difficult because CF has numerous
phenotypes and genotypes. Therefore, the use of a single tool
for diagnosis is complex and dubious. This fact is even more
significant in developing countries.
The diagnosis and management of CF in Brazil show
variability among CF reference centers. Many problems still
exist, such as (i) a high proportion of undiagnosed cases,
(ii) delayed diagnosis in many states, (iii) limited services
in relation to the actual demand, (iv) a small number of
health professionals involved, (iv) disease underestimates
by health authorities (low investments and reduced current
expenditures), (v) a lack of NBS in most states, and (vi)
scientific production that remains limited [41].
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Table 2: Clinical and laboratory characteristics of the cystic fibrosis patients enrolled in the study.
Clinical markers∗ G1 G2 𝑃 value
Gender (male) 5 2 1
Race (Caucasian) 10 5 —
Age (months) 210.60 ± 132.01; 146 (87–443) 336.40 ± 119.13; 336 (170–480) 0.099
Onset of symptoms (months) 8.20 ± 15.50; 1 (0–39) 3.75 ± 4.86; 1.50 (1–11) 0.454
Onset of pulmonary symptoms (months) 13.60 ± 22.26; 4 (0–69) 4 ± 4.97; 2.50 (0–11) 0.539
Onset of digestive symptoms (months) 23.70 ± 41.51; 1 (0–120) 1 ± 1.41; 1 (0–2) 0.758
Diagnosis (months) 36.10 ± 47.24; 17 (1–144) 99.25 ± 8.50; 185.88 (2–378) 1
Body mass index (normal values) 9 3 0.242
Nasal polyposis (presence) 1 2 0.242
Diabetes mellitus (presence) 2 — 0.524
Osteoporosis (presence) 1 2 0.242
Pancreatic insufficiency (presence) 10 3 0.095
Meconium ileus (presence) 3 — 0.505
Pseudomonas aeruginosa 6 4 0.600
Mucoid P. aeruginosa 4 4 0.282
Achromobacter xylosoxidans 2 — 0.524
Burkholderia cepacia 3 1 1
Staphylococcus aureus 9 3 0.242
Weight (kg) 41.50 ± 17.51; 36 (21–66) 48 ± 16.98; 50 (27–70) 0.513
Height (m) 1.74 ± 0.43; 2 (1-2) 1.50 ± 0.53; 1.50 (1-2) 0.594
Body mass index 18.54 ± 3.18; 19.95 (14.38–21.60) 18.25 ± 2.56; 18.48 (14.34–21.31) 0.768
SpO2 96.10 ± 1.45; 96 (94–98) 96 ± 2.31; 96 (94–98) 1
Bhalla 8 ± 4.74; 7 (0–17) 12.50 ± 3.53; 12.50 (10–15) 0.327
Kanga 19 ± 4.82; 19 (12–25) 30.50 ± 20.17; 23.50 (15–60) 0.260
Shwachman-Kulczycki 68.50 ± 13.34; 65 (50–90) 71.67 ± 10.40; 75 (60–80) 0.811
FVC 91.80 ± 20.02; 87.50 (69–131) 70.20 ± 20.17; 63 (57–106) 0.028
FEV1 85.10 ± 22.41; 75.50 (64–132) 59 ± 25.40; 60 (30–95) 0.055
FEV1/FVC 82.60 ± 18.92; 85.50 (37–100) 67.75 ± 17.58; 71 (46–83) 0.106
FEF
25–75% 71.40 ± 30.85; 66 (33–118) 45.50 ± 24.78; 47.50 (17–70) 0.188
∗The data are shown as 𝑁 (percentage) for the categorical data; the statistical analysis consisted of the 𝜒2 test and Fisher’s exact test; the mean ± standard
deviation and median (minimum and maximum) values were used for the numerical data that was analyzed by the Mann-Whitney 𝑈 test. 𝑁: number of
patients; SpO2: blood oxygen saturation; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; FEF25–75%: forced expiratory flow
between 25 and 75% of the FVC. G1: cystic fibrosis patients with two class I, II, or III CFTR mutations; G2: cystic fibrosis patients with at least one class IV, V,
or V CFTRmutation.
To the best of our knowledge, this is the first study con-
ducted in Brazil to evaluate NPD in CF patients diagnosed by
screening two CFTR mutations in comparison with healthy
subjects. Our study showed that measuring NPD can differ-
entiate CF patients with two severe mutations from healthy
subjects. However, it was not able to identify differences
between patients with class I, II, or III (greater severity) and
thosewith class IV,V, orVI (minor severity)CFTRmutations.
Studies have shown that the electronegativity of organs
and systems in CF patients is compromised, depending on
the CFTR mutation class. This causes variations in sweat
chloride values among different CFTRmutation classes [20].
Measurements of functional CFTR protein in human models
for diagnosis, prognosis, and personalized therapy have been
initiated and used and are a step forward in the manage-
ment of CF [27]. Among these tools, the CFTR biomarker-
like nasal transepithelial potential (NTP); sweat test; rectal
transepithelial Cl− Secretion; and evaporimetry have been
studied and stimulated in several centers [27, 42], including
our university. These tools have proven useful in the analysis
of functional alterations in the CFTR protein in CF patients
with class I, II, or III mutations in the CFTR gene (severe and
classical CF) compared with healthy individuals. However,
these tools are not able to separate healthy individuals from
patients with genotypes arising from class IV, V, or VI
mutations (minor severity and nonclassical CF).
All of these tools show reproducibility/reliability, respon-
siveness, limitations, feasibility, and availability that limit
their application as routine indications in the diagnosis of CF
management. Respiratory NPD is by far the most extensively
validated CFTR biomarker [27]. In contrast, we showed that
NTP was useful for differentiating individuals with severe
CF from healthy subjects; however, it was not useful for
differentiating individuals with mild mutations. Therefore,
with the advent of correctors and potentiators for the CFTR
protein that are specific for each CFTR genotype, this tool
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became necessary to evaluate the efficiency and effectiveness
of new drugs for CF, as has been shown by recent studies.
However, its use in clinical practice for CF diagnosis is
unclear and should be revised and studied further.
Considering the difficulty of characterizing CF patient
groups with class IV, V, or VI mutations, taking into account
the possibility of normal TNM values and sweat test, in
association with the residual expression of the CFTR protein,
new diagnostic tools should be provided, and a potential tool
is NPD [28]. If we consider this hypothesis, electrophysiology
studieswould be importantmarkers to confirmCFTRprotein
dysfunction but not a diagnostic marker for the disease.
With the introduction of NBS in our state in 2010, chil-
dren with severe mutations are likely to have early diagnosis
confirmed and will be attended at reference centers.
Based on a positive NBS, followed by two chlorine values
greater than 60mEq/L, we obtained CF diagnoses for most
CF patients with severe mutations (class I, II, or II). The
molecular analysis ofCFTRmutationsmay help in increasing
specific knowledge about our population, where 61.9% of
patients have at least one F508del mutation and 26.7% have
two F508del alleles [26].
In our study, theWilschanski index showed thatNPDwas
significantly different between GA andGC; in this case, it can
be useful for CF diagnosis in patients with two class I, II, or
III mutations. Therefore, it cannot be inferred that NPD is a
diagnostic test for CF, taking into account that patients with
class IV, V, or VImutations (GB) are not differentiated by this
technique in comparisonwith the other groups (GA andGC).
The only possible test for certain CF diagnosis in all cases
would be CFTR gene sequencing.
Considering future prospects, other methods to assess
CFTR function have been proposed in the literature, such
as beta-adrenergic function studies of the sweat glands [19].
Studies in this line of research are focusing on cases where
CF diagnosis is performed and sweat chloride values are
normal and it is not possible to identify CFTR mutations by
sequencing, considering the technical costs.
The limitations of the present study were that (i) NPD
was performed without considering the SOP-NPD, (ii) there
were a low number of patients in the GB, with negative results
for the association that indicates nonerroneous data, and (iii)
there was no association with other CF diagnosis tools.
5. Conclusions
NPD showed significantly different values between CF
patients with two severe CFTR mutations of known classes
and healthy individuals. However, NPDdoes not differentiate
between those with severe CFTR mutations from other CF
patients with minor but serious mutations. The NPD should
not be used as diagnosis tool for CF patients with class IV-VI
CFTRmutations. Thus, our proposal that neonatal screening
by IRT, followed by the sweat test and screening of the
classic F5008del mutation, appears to be satisfactory for the
diagnosis of CF in our country. It is quite likely that NPDwill
be able to assess the improved function of ionic permeability
in the cells of the respiratory tract by the action of potentiator
CFTR drugs, such as ivacaftor, but not the diagnosis of CF, as
our results have shown.
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